Trials / No Longer Available
No Longer AvailableNCT03914261
Expanded Access to Risankizumab
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- AbbVie · Industry
- Sex
- —
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an expanded access program (EAP) for eligible participants with Crohn's Disease (CD). This program is designed to provide access to risankizumab, prior to approval by the local regulatory agency, to patients with the highest unmet need and an urgent need for treatment, where risankizumab may prolong survival, prevent occurrence of clinical events associated with significant morbidity and/or mortality, or stabilize a progressive debilitating disease. Availability will depend on a review of the eligibility of the patient and local approval status of risankizumab for CD. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Risankizumab | Tablet |
Timeline
- First posted
- 2019-04-16
- Last updated
- 2022-05-24
Source: ClinicalTrials.gov record NCT03914261. Inclusion in this directory is not an endorsement.